Safety of high dose bedaquiline treatment in patients with extensively drug-resistant tuberculosis

Extract: Bedaquiline (Bdq) was authorised for the treatment of multidrug-resistant (MDR) tuberculosis (TB) in 2014 in Europe. It is part of the preferred BPaLM regimen (Bdq, pretomanid, linezolid (Lzd), moxifloxacin (Mfx)), of individualised MDR-TB treatment and new MDR-TB regimens recommended by th...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Peterka, Manuel (Autore) , Krieger, David (Autore) , Khatamzas, Elham (Autore) , Denkinger, Claudia M. (Autore) , Köhler, Niklas (Autore) , Lange, Christoph (Autore) , Macholz, Martin (Autore) , Lübbert, Christoph (Autore) , Daller, Simon (Autore) , Knappik, Michael (Autore) , Kuhns, Martin (Autore) , Häcker, Brit (Autore) , Polsfuß, Silke (Autore) , Bauer, Torsten (Autore) , Otto-Knapp, Ralf (Autore)
Natura:	Article (Journal) Editorial
Lingua:	inglese
Pubblicazione:	2026
In:	The European respiratory journal Year: 2026, Volume: 67, Fascicolo: 1, Pages: 1-5
ISSN:	1399-3003
DOI:	10.1183/13993003.01496-2025
Accesso online:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1183/13993003.01496-2025 Verlag, lizenzpflichtig, Volltext: https://publications.ersnet.org/content/erj/67/1/2501496
Note sull'autore:	Manuel Peterka, David Krieger, Elham Khatamzas, Claudia M. Denkinger, Niklas Köhler, Christoph Lange, Martin Macholz, Christoph Lübbert, Simon Daller, Michael Knappik, Martin Kuhns, Brit Häcker, Silke Polsfuß, Torsten Bauer and Ralf Otto-Knapp